As election year looms, Democrats lever drug pricing bill through HouseThe US House of Representatives passed a bill that will allow the federal government to negotiate drug prices, Share XAs election year looms, Democrats lever drug pricing bill through Househttps://pharmaphorum.com/news/as-election-year-looms-democrats-lever-drug-pricing-bill-through-house/
ABPI looks internally for new CEO, naming Richard TorbettThe new chief executive of the Association of the British Pharmaceutical Industry (ABPI) will be Dr Richard Torbett Share XABPI looks internally for new CEO, naming Richard Torbetthttps://pharmaphorum.com/news/abpi-looks-internally-for-new-ceo-naming-richard-torbett/
W2O acquisitions continue as it buys Radius Digital ScienceW2O has made its third acquisition in recent months, buying Radius Digital Science, a New Jersey-based scientific creative Share XW2O acquisitions continue as it buys Radius Digital Sciencehttps://pharmaphorum.com/news/w2o-radius-digital-science/
Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
Claire Gillis wins Women in Marketing health leadership prizeWPP’s health practice international CEO Claire Gillis picked up the inaugural healthcare marketing leadership prize at last night’s Share XClaire Gillis wins Women in Marketing health leadership prizehttps://pharmaphorum.com/news/claire-gillis-women-in-marketing-award/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Open Health merges with HEOR and market access firm PharmeritOpen Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move Share XOpen Health merges with HEOR and market access firm Pharmerithttps://pharmaphorum.com/news/open-health-merger-heor-pharmerit/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
